Core Viewpoint - Hantian Aitai-B (03378) has made its debut on the stock market with an initial share price of HKD 32, issuing 18.321 million shares and raising approximately HKD 531 million, but the stock has seen a decline of 9.69% to HKD 28.9 at the time of reporting [1] Company Overview - Hantian Aitai is a biotechnology company specializing in structural biology, translational medicine, and clinical development, with a product pipeline that includes one core product and nine other candidate products [1] - The company has developed three clinical-stage candidates targeting oncology, including the core product HX009 and major products HX301 and HX044, as well as seven preclinical candidates targeting autoimmune and oncology markets [1] Product Details - The core product HX009 is a bispecific antibody fusion protein that targets both CD47 and PD-1 [1] - According to a Frost & Sullivan report, HX009's clinical trial progress is leading globally among similar CD47-targeting bispecific antibody/bifunctional fusion protein products as of the last feasible date [1]
新股首日 | 翰思艾泰-B(03378)首挂上市 早盘低开9.69% 核心产品HX009正在中国进行三个临床项目